Literature DB >> 7570734

Costs of medical care after first-ever stroke in The Netherlands.

L Bergman1, J H van der Meulen, M Limburg, J D Habbema.   

Abstract

BACKGROUND AND
PURPOSE: Stroke causes high morbidity and mortality. The aging of the population further increases the demands on healthcare costs.
METHODS: We estimated the lifetime direct costs of care of first-ever stroke patients in the Netherlands in 1991 using epidemiological data from national and international studies. In addition, we examined the effect of an aging population on future healthcare costs.
RESULTS: The lifetime costs for 24,007 first-ever stroke patients are estimated to be 1870 million Dutch guilders (Dfl) (1 Dfl = 0.53 US dollar, 1991). Per-person costs are higher for women (83,000 Dfl) than for men (71,000 Dfl). The major cost component of first-year costs is hospital costs (45%), while nursing home costs dominate lifetime costs (50%). An increase of the elderly population older than 65 years of 27% between 1991 and 2010 might lead to a parallel increase of total costs of 30%, or 1.5% per year.
CONCLUSIONS: Long-term care rather than acute care dominates the lifetime costs for stroke patients now and in the future.

Entities:  

Mesh:

Year:  1995        PMID: 7570734     DOI: 10.1161/01.str.26.10.1830

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  17 in total

Review 1.  The relationship between cholesterol and stroke: implications for antihyperlipidaemic therapy in older patients.

Authors:  C Sarti; M Kaarisalo; J Tuomilehto
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

2.  Hospital costs of ischemic stroke and TIA in the Netherlands.

Authors:  Leander R Buisman; Siok Swan Tan; Paul J Nederkoorn; Peter J Koudstaal; William K Redekop
Journal:  Neurology       Date:  2015-05-01       Impact factor: 9.910

Review 3.  Aspirin and heparin in acute ischaemic stroke in older patients.

Authors:  G J Gubitz; P A Sandercock
Journal:  Drugs Aging       Date:  1999-07       Impact factor: 3.923

4.  Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole.

Authors:  M Chambers; J Hutton; J Gladman
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

Review 5.  Thrombolysis, stroke units and other strategies for reducing acute stroke costs.

Authors:  T H Wein; S L Hickenbottom; A V Alexandrov
Journal:  Pharmacoeconomics       Date:  1998-12       Impact factor: 4.981

6.  Off-pump coronary artery bypass surgery compared with stent implantation and on-pump bypass surgery: clinical outcome and cost-effectiveness at one year.

Authors:  H M Nathoe; D van Dijk; E W L Jansen; C Borst; D E Grobbee; P P T de Jaegere
Journal:  Neth Heart J       Date:  2005-08       Impact factor: 2.380

Review 7.  Long term cost-of-illness in stroke: an international review.

Authors:  Krista A Payne; Krista F Huybrechts; J Jaime Caro; Traci J Craig Green; Wendy S Klittich
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

8.  Effect of upper airway obstruction in acute stroke on functional outcome at 6 months.

Authors:  P M Turkington; V Allgar; J Bamford; P Wanklyn; M W Elliott
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

9.  The cost of materials for intra-arterial thrombectomy.

Authors:  F Bing; G Jacquin; A Poppe; D Roy; J Raymond; A Weill
Journal:  Interv Neuroradiol       Date:  2013-03-04       Impact factor: 1.610

Review 10.  The medical economics of stroke.

Authors:  T N Taylor
Journal:  Drugs       Date:  1997       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.